According to a recent study, AXL is stimulated by osimertinib after the termination of a negative feedback loop into SPRY4 in EGFR‐mutant lung cancer cells, resulting in the expression of HER3 and EGFR to maintain cell survival and promote osimertinib tolerance.220. Here, EGFR is linked to lung carcinoma.